A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study Of Oral Pf-06651600 And Pf-06700841 As Induction And Chronic Therapy In Subjects With Moderate To Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Vibrato
- Sponsors Pfizer
- 20 Mar 2017 Planned End Date changed from 1 Jan 2020 to 28 Jan 2020.
- 20 Mar 2017 Planned primary completion date changed from 1 Jul 2019 to 12 Jul 2019.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting.